These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2954605)

  • 1. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
    Mauriac L; Coste P; Richaud P; Lamarche P; Mage P; Bonichon F
    Am J Clin Oncol; 1988; 11 Suppl 2():S117-9. PubMed ID: 2977265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.
    Ahmed SR; Grant J; Shalet SM; Howell A; Chowdhury SD; Weatherson T; Blacklock NJ
    Br Med J (Clin Res Ed); 1985 Jan; 290(6463):185-7. PubMed ID: 3155636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
    Murphy GP; Greco J; Huben R
    Urology; 1987 Nov; 30(5):482-3. PubMed ID: 2960064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
    Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
    J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
    Kerle D; Williams G; Ware H; Doble A; Allen J; Bloom SR
    Br J Urol; 1984 Oct; 56(5):495-8. PubMed ID: 6242022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
    Perren TJ; Clayton RN; Blackledge G; Bailey LC; Holder G; Lynch SS; Arkell DG; Cottam J; Farrar D; Young CH
    Cancer Chemother Pharmacol; 1986; 18(1):39-43. PubMed ID: 2944668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
    Schulze H; Senge T
    J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
    Metz R; Namer M; Adenis L; Audhuy B; Bugat R; Colombel P; Couette JE; Grise P; Khater R; LePorz B
    Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoladex (ICI 118,630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma.
    Murphy GP; Greco JM; Chin JL; Huben RP; Scott M; deHaan HA
    Urology; 1987 Feb; 29(2):185-90. PubMed ID: 2949417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer.
    Mahler C; Denis L
    Am J Clin Oncol; 1988; 11 Suppl 2():S127-8. PubMed ID: 2977268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
    Grifoni R; Pierangeli T
    Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
    Debruyne FM; Denis L; Lunglmayer G; Mahler C; Newling DW; Richards B; Robinson MR; Smith PH; Weil EH; Whelan P
    J Urol; 1988 Oct; 140(4):775-7. PubMed ID: 2971119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
    Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
    Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.